Diabetes

Esaxerenone is a nonsteroidal mineralocorticoid receptor blocker that is being studied for its effectiveness for diabetes-associated mineralocorticoid receptor-related hypertension.

The results show promise, as vision typically improves the most during the first 4 weeks, but with lamivudine, vision continued to improve in the following 4 weeks.

Razanne Oueini, PharmD, MSc, CPHQ, discusses how rates of persistence to basal insulin were impacted after the IRA monthly cap.

Kaitlin Bates, PharmD, discusses the results of implementing a program used to support standardized pharmacy quality measures.

A conversation with Razanne Oueini, PharmD, MSc, CPHQ, senior manager of Performance Measurement at PQA, at PQA 2025.

Insulin delivery technology company Sequel Med Tech announced its future partnership with Abbott’s glucose-ketone sensor, which is currently under development.

A conversation with Kaitlin Bates, PharmD, ARHOME Quality Manager at Arkansas Blue Cross and Blue Shield, at PQA 2025.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Abbott’s continuous glucose monitoring system is the first to show a reduction in cardiovascular complication severity.

Investigators also find that patients diagnosed with type 1 diabetes later in life do not have a better prognosis compared to those diagnosed earlier.

Investigators also found that nocturnal hypoglycemia is a strong predictor of daytime hypoglycemia.

Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.

A conversation with Casey Koch, PharmD, MBA, BCACP, clinical pharmacy coordinator at SelectHealth, at Asembia’s AXS25 Summit.

A conversation with Becky Davis, principal at Charles River Associates, at Asembia’s AXS25 Summit.

In the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.

This method supports improved, early detection for diabetes without relying on blood samples or complex procedures.

Further, the authors of the “Standards of Care in Diabetes 2025” highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Investigators find that orforglipron lowered A1c by an average of 1.3% to 1.6% from a baseline of 8% across 3 different dosages.

Furthermore, C-reactive protein has greater prognosis for lung cancer, colorectal cancer, and ovarian cancer.

A conversation with Scott Biggs and Greg Mitchell at the American Associated Pharmacies 2025 Annual Conference.